2. Search Result
Search Result
Results for "

MOLM-14

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-148669A
    Bleximenib oxalate

    JNJ-75276617 oxalate; Menin-MLL inhibitor 24 oxalate

    		 Epigenetic Reader Domain Apoptosis Cancer
    Bleximenib (JNJ-75276617; Menin-MLL inhibitor 24) oxalate is a potent, selective and orally active menin-KMT2A protein-protein interaction inhibitor with IC50 values of 0.1, 0.045, ≤0.066 nM for human, mouse, dog, respectively. Bleximenib oxalate shows antiproliferative activity and induces apoptosis. Bleximenib oxalate has the potential for the research of Acute myeloid leukemia (AML) .
    Bleximenib oxalate
  • HY-148669
    Bleximenib

    JNJ-75276617; Menin-MLL inhibitor 24

    		 Epigenetic Reader Domain Apoptosis Cancer
    Bleximenib (JNJ-75276617; Menin-MLL inhibitor 24) is a potent, selective and orally active menin-KMT2A protein-protein interaction inhibitor with IC50 values of 0.1, 0.045, ≤0.066 nM for human, mouse, dog, respectively. Bleximenib shows antiproliferative activity and induces apoptosis. Bleximenib has the potential for the research of Acute myeloid leukemia (AML) .
    Bleximenib
  • HY-170361
    MTHFD2-IN-5

    		Methylenetetrahydrofolate Dehydrogenase (MTHFD) Cancer
    MTHFD2-IN-5 (Compound 16e) is a selective inhibitor for MTHFD2 with an IC50 of 66 nM. MTHFD2-IN-5 inhibits the proliferation of MOLM-14 with a GI50 of 720 nM. MTHFD2-IN-5 exhibits antitumor efficacy in mouse models .
    MTHFD2-IN-5
  • HY-155245
    A09-003

    		CDK Bcl-2 Family Cancer
    A09-003 is a CDK-9 inhibitor (IC50: 16 nM). A09-003 inhibits leukemia cell proliferation (IC50: 1.90, 0.86, 2.49, 1.84, 0.48 μM for BDCM, Molm-14, THP-1, U937, MV4-11 cells). A09-003 induces apoptosis and decreases Mcl-1 expression through Thr163 dephosphorylation .
    A09-003
  • HY-164977
    JCS-1

    		PROTACs Phosphatase Cancer
    JCS-1 is a potent DcpS PROTAC degrader. JCS-1 non-covalently binds DcpS with a RG3039-based warhead and recruits the E3 ligase VHL. JCS-1 promotes ubiquitination and degradation of DcpS at nanomolar concentrations (DC50 in MOLM-14 cells: 87 nM). JCS-1 can be used for the research of AML and other DcpS-dependent genetic disorders (Pink: DcpS ligand (HY-102020); Blue: E3 ligase VHL ligand (HY-151227); Black: linker (HY-141230)) .
    JCS-1
  • HY-170953
    QXG-6442

    		Casein Kinase Molecular Glues Cancer
    QXG-6442 is a CK1α Molecular Glue Degrader. QXG-6442 exhibits CK1α degradation potency with a DC50 of 5.7 nM and a Dmax of 90%. QXG-6442 induces antiproliferative effects in MOLM-14 cell line .
    QXG-6442
  • HY-170576
    FLT3-IN-28

    		FLT3 STAT Apoptosis Cancer
    FLT3-IN-28 (Compound 12y) is an orally active FLT3 inhibitor with antitumor activity. FLT3-IN-28 selectively inhibits cancer cells harboring the FLT3 internal tandem duplication (ITD) mutation, with IC50 values of 85, 290, 130, 65, and 220 nM for BaF3-FLT3-ITD, BaF3-TEL-VEGFR2, MV4-11, MOLM-13, and MOLM-14 cell lines respectively (MV4-11 and MOLM-13/14 are acute myeloid leukemia (AML) cell lines carrying the FLT3-ITD mutation). Additionally, FLT3-IN-28 can downregulate the phosphorylation levels of FLT3 and STAT5 in MOLM-13 cells and induce cell cycle arrest and Apoptosis. FLT3-IN-28 has an oral bioavailability of 19.2% in SD rats and can prolong survival in a dose-dependent manner in NSG mice xenografted with MOLM-13 cells. FLT3-IN-28 holds promise for research in cancer fields related to FLT3-ITD .
    FLT3-IN-28
  • HY-168654
    WEE1 degrader 1

    		Wee1 Cancer
    WEE1 degrader 1 (Compound 10) is a Wee1 degrader with a DC50 value of 1.5 nM against Wee1. WEE1 degrader 1 possesses anti-cancer cell proliferation effects .
    WEE1 degrader 1
  • HY-143434
    FLT3/D835Y-IN-1

    		FLT3 Cancer
    FLT3/D835Y-IN-1 (compound 13a) is a orally active, potent and selective FLT3 and FLT3/D835Y inhibitor, with IC50 values of 0.26 nM and 0.18 nM, respectively. FLT3/D835Y-IN-1 also blocks tumor growth, has anticancer efficacy, and can be used to research for AML (acute myeloid leukemia) .
    FLT3/D835Y-IN-1
  • HY-163678
    Pomalidomide-CO-C7-NH-CO-C3-COOH

    		E3 Ligase Ligand-Linker Conjugates Cancer
    Pomalidomide-CO-C7-NH-CO-C3-COOH is a conjugate of a ligand for E3 ligase and a linker. Pomalidomide-CO-C7-NH-CO-C3-COOH can be used for synthesis of PROTAC degrader ARM165 (HY-163677) .
    Pomalidomide-CO-C7-NH-CO-C3-COOH
  • HY-163677
    ARM165

    		PROTACs PI3K Akt Cancer
    ARM165 is a heterobifunctional molecule. ARM165 degrades the PIK3CG proteins, inhibits PI3Kγ-Akt signaling pathway, and thus exhibits antileukemia efficacy. ARM165 inhibits proliferations of AML cells, with IC50 <1 μM. (Pink: ligand for target protein PI3Kγ inhibitor AZ2 (HY-111570); Black: linker; Blue: ligand for E3 ligase Pomalidomide (HY-10984))
    ARM165
  • HY-129239
    Farudodstat
    2 Publications Verification

    ASLAN003

    		 Dihydroorotate Dehydrogenase DNA/RNA Synthesis Apoptosis Cancer
    Farudodstat (ASLAN003) is an orally active and potent Dihydroorotate Dehydrogenase (DHODH) inhibitor with an IC50 of 35 nM for human DHODH enzyme. Farudodstat inhibits protein synthesis via activation of AP-1 transcription factors. Farudodstat induces apoptosis and substantially prolongs survival in acute myeloid leukemia (AML) xenograft mice .
    Farudodstat

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: